Page 8 - Flipbook
P. 8
DASL-HiCaP: Darolutamide Augments
Standard Therapy for Localised Very
High-Risk Cancer of the Prostate
(ANZUP1801)
A randomized phase 3 double-blind,
placebo-controlled trial of adding
DARO to ADT and definitive or salvage
RT in very high risk, clinically localised
prostate cancer
PR 22
